🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
MRNA
NASDAQ
🇺🇸 US
Moderna, Inc.
Pharmaceuticals
28Score
DipBuster Score™
$231.26
+$10.43 (+4.72%)
Live price · Source: Yahoo
52-Week Position
$22.28
90% of range
$254.48
Beta
0.899
Market-like
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.899
52W High$254.48
52W Low$22.28
DipBuster Brief
Key signals at a glance
Zone: Sell / Avoid
Bearish
Near 52-Week High — Asymmetric Risk
At 90% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position90% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.899
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Moderna, Inc. (MRNA), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-10-15 | Hoge Stephen | SELL | 76,452 |
| 2026-10-15 | Hoge Stephen | SELL | 39,145 |
| 2026-10-15 | Hoge Stephen | BUY | 76,452 |
| 2026-10-14 | Hoge Stephen | SELL | 76,453 |
| 2026-10-14 | Hoge Stephen | SELL | 450 |
| 2026-10-14 | Hoge Stephen | SELL | 38,774 |
| 2026-10-14 | Hoge Stephen | BUY | 76,453 |
| 2026-10-05 | Mock James M | SELL | 1,454 |
| 2026-10-05 | Mock James M | SELL | 704 |
| 2026-10-05 | Mock James M | BUY | 1,454 |
Graham NCAV Analysis
Above net-net level
Current Assets$6.54B
Less: Total Liabilities−$3.69B
= Net Current Asset Value$2.86B
NCAV Per Share$7.2487
Current Price$221.72
Price / NCAV30.59×
Margin of Safety-2958.7%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.899
Dividend/yrNone
52W High$254.48
52W Low$22.28
52-Week Range
$22.28Now$254.48
90% through annual range
From 52W High−9.1%
From 52W Low+938%
📖 Plain English Summary
Moderna, Inc. is at 90% of its 52-week range. Beta 0.899 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for MRNA
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — MRNA
Heuristic · balance sheet, insider filings, price data, academic research
Moderna, Inc. — DipBuster Score 28/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Moderna, Inc. free
Add MRNA to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
4/25
Momentum & Volume
19/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
0
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 28/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts targ…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Stéphane Bancel
Staff
4,700 employees
Website